Cargando…

A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules

A specific labeling strategy for bioactive molecules is presented for eptifibatide (integrilin) an antiplatelet aggregation inhibitor, which derives from the disintegrin protein barbourin in the venom of certain rattlesnakes. By specifically labeling the disulfide bridge this molecule becomes access...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleckenstein, Max, Herr, Kevin, Theiß, Franziska, Knecht, Stephan, Wienands, Laura, Brodrecht, Martin, Reggelin, Michael, Buntkowsky, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837631/
https://www.ncbi.nlm.nih.gov/pubmed/35149768
http://dx.doi.org/10.1038/s41598-022-06327-z
_version_ 1784649956882120704
author Fleckenstein, Max
Herr, Kevin
Theiß, Franziska
Knecht, Stephan
Wienands, Laura
Brodrecht, Martin
Reggelin, Michael
Buntkowsky, Gerd
author_facet Fleckenstein, Max
Herr, Kevin
Theiß, Franziska
Knecht, Stephan
Wienands, Laura
Brodrecht, Martin
Reggelin, Michael
Buntkowsky, Gerd
author_sort Fleckenstein, Max
collection PubMed
description A specific labeling strategy for bioactive molecules is presented for eptifibatide (integrilin) an antiplatelet aggregation inhibitor, which derives from the disintegrin protein barbourin in the venom of certain rattlesnakes. By specifically labeling the disulfide bridge this molecule becomes accessible for the nuclear spin hyperpolarization method of parahydrogen induced polarization (PHIP). The PHIP-label was synthesized and inserted into the disulfide bridge of eptifibatide via reduction of the peptide and insertion by a double Michael addition under physiological conditions. This procedure is universally applicable for disulfide-containing biomolecules and preserves their tertiary structure with a minimum of change. HPLC and MS spectra prove the successful insertion of the label. (1)H-PHIP-NMR experiments yield a factor of over 1000 as lower limit for the enhancement factor. These results demonstrate the high potential of the labeling strategy for the introduction of site selective PHIP-labels into biomolecules’ disulfide bonds.
format Online
Article
Text
id pubmed-8837631
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88376312022-02-14 A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules Fleckenstein, Max Herr, Kevin Theiß, Franziska Knecht, Stephan Wienands, Laura Brodrecht, Martin Reggelin, Michael Buntkowsky, Gerd Sci Rep Article A specific labeling strategy for bioactive molecules is presented for eptifibatide (integrilin) an antiplatelet aggregation inhibitor, which derives from the disintegrin protein barbourin in the venom of certain rattlesnakes. By specifically labeling the disulfide bridge this molecule becomes accessible for the nuclear spin hyperpolarization method of parahydrogen induced polarization (PHIP). The PHIP-label was synthesized and inserted into the disulfide bridge of eptifibatide via reduction of the peptide and insertion by a double Michael addition under physiological conditions. This procedure is universally applicable for disulfide-containing biomolecules and preserves their tertiary structure with a minimum of change. HPLC and MS spectra prove the successful insertion of the label. (1)H-PHIP-NMR experiments yield a factor of over 1000 as lower limit for the enhancement factor. These results demonstrate the high potential of the labeling strategy for the introduction of site selective PHIP-labels into biomolecules’ disulfide bonds. Nature Publishing Group UK 2022-02-11 /pmc/articles/PMC8837631/ /pubmed/35149768 http://dx.doi.org/10.1038/s41598-022-06327-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Fleckenstein, Max
Herr, Kevin
Theiß, Franziska
Knecht, Stephan
Wienands, Laura
Brodrecht, Martin
Reggelin, Michael
Buntkowsky, Gerd
A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules
title A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules
title_full A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules
title_fullStr A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules
title_full_unstemmed A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules
title_short A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules
title_sort disintegrin derivative as a case study for phip labeling of disulfide bridged biomolecules
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837631/
https://www.ncbi.nlm.nih.gov/pubmed/35149768
http://dx.doi.org/10.1038/s41598-022-06327-z
work_keys_str_mv AT fleckensteinmax adisintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT herrkevin adisintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT theißfranziska adisintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT knechtstephan adisintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT wienandslaura adisintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT brodrechtmartin adisintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT reggelinmichael adisintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT buntkowskygerd adisintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT fleckensteinmax disintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT herrkevin disintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT theißfranziska disintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT knechtstephan disintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT wienandslaura disintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT brodrechtmartin disintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT reggelinmichael disintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules
AT buntkowskygerd disintegrinderivativeasacasestudyforphiplabelingofdisulfidebridgedbiomolecules